Peeling the I-Onion to Demystify Pseudoprogression

Erica S Tsang; Lillian L Siu

doi:10.1016/j.ccell.2023.08.003

Peeling the I-Onion to Demystify Pseudoprogression

Cancer Cell. 2023 Sep 11;41(9):1545-1547. doi: 10.1016/j.ccell.2023.08.003.

Authors

Erica S Tsang¹, Lillian L Siu²

Affiliations

¹ Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada. Electronic address: erica.tsang@uhn.ca.
² Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

PMID: 37699332
DOI: 10.1016/j.ccell.2023.08.003

Abstract

In this issue of Cancer Cell, Topp et al. analyze data from 799 patients treated with pembrolizumab beyond progression by RECIST 1.1 across six trials. Although 8.9%-24.4% of patients demonstrate a ≥30% reduction in target lesions, conversely 11%-18% of patients had a ≥20% increase. The benefits of treatment beyond progression must be carefully weighed against physical and financial toxicities.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Disease Progression*
Humans
Neoplasms* / drug therapy

Substances

pembrolizumab